Oscar Health (OSCR) AI Stock Analysis

• Market Cap: $4.81B
• Dividend Yield: N/A
• Average Volume (3M): 16.81M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.76
• Revenue Growth: 37.38%
• EPS Growth: -912.18%
• Country: US
• Employees: 2,400
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Healthcare Plans
• EPS (TTM): -0.53
• Shares Outstanding: 229,010,000
• 10 Day Avg. Volume: 17,362,904
• 30 Day Avg. Volume: 16,814,263
• PEG Ratio: -1.17
• Price to Book (P/B): 3.19
• Price to Sales (P/S): 0.35
• P/FCF Ratio: 3.40
• Enterprise Value/Market Cap: 1.16
• Enterprise Value/Revenue: 0.50
• Enterprise Value/Gross Profit: 0.50
• Enterprise Value/Ebitda: -30.53
• 1Y Price Target: $16.06
• Price Target Upside: -11.56% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 5
• EPS Forecast (FY): -1.29
• Revenue Forecast (FY): $11.95B

• Rating: 45 Neutral
• Price Target: $14.50 ▼(-20.15% Downside)

Oscar Health's overall stock score is primarily impacted by its financial performance and valuation challenges. Despite revenue growth and membership expansion, the company's profitability issues and negative cash flow position weigh heavily on its score. Technical analysis provides a neutral outlook, but the negative P/E ratio and lack of dividend yield further detract from its attractiveness. The earnings call highlights potential future improvements, but current financial metrics remain a concern.

Positive Factors

Revenue Growth

The significant revenue growth indicates strong market demand and effective business strategies, supporting long-term financial stability and expansion.

Membership Increase

The growth in membership base enhances revenue potential and market presence, contributing to sustainable business growth and competitive positioning.

Innovative Products and AI Integration

The introduction of innovative products and AI integration can improve customer experience and operational efficiency, driving long-term competitive advantage.

Negative Factors

Profitability Challenges

Ongoing operational losses indicate challenges in achieving profitability, which may affect long-term financial health and investment capacity.

Medical Loss Ratio Increase

The rising medical loss ratio suggests increasing costs relative to premiums, potentially impacting margins and financial sustainability.

Cash Flow Concerns

Weak cash flow generation limits financial flexibility and may hinder the company's ability to invest in growth opportunities and manage debt.

Oscar Health Business Overview & Revenue Model

Company Description

Oscar Health (OSCR) is a health insurance company focused on providing innovative, technology-driven health care solutions. Operating primarily in the health insurance sector, Oscar Health aims to simplify the health insurance experience through user-friendly digital platforms and personalized care management. The company offers individual and family health plans, employer-sponsored insurance, and Medicare Advantage plans, emphasizing transparency and accessibility in health care services.

How the Company Makes Money

Oscar Health generates revenue primarily through premiums collected from policyholders who enroll in its health insurance plans. The company earns money by charging monthly premiums to individuals and families for coverage, as well as from employer contributions in the case of group plans. Oscar also receives reimbursement from the federal government for Medicare Advantage members. Additional revenue streams may include ancillary services, such as telehealth offerings, and value-based care arrangements that incentivize Oscar to improve patient health outcomes while managing costs. Key partnerships with health care providers and technology platforms further enhance Oscar's ability to deliver value and potentially increase its earnings.

Oscar Health Financial Statement Overview

Summary

Oscar Health is experiencing revenue growth, but profitability and cash flow remain significant challenges. The balance sheet shows moderate leverage and a healthy equity ratio, but the negative return on equity and declining cash flows highlight the need for strategic improvements. The company must focus on enhancing profitability and cash flow generation to strengthen its financial position.

Income Statement

Oscar Health has shown a moderate revenue growth rate of 5.24% in the TTM, indicating some positive momentum. However, the company is struggling with profitability, as evidenced by negative net profit and EBIT margins. The gross profit margin is relatively low at 21.20%, suggesting high cost structures. Overall, while revenue is growing, profitability remains a significant challenge.

Balance Sheet

The company's debt-to-equity ratio of 0.67 in the TTM indicates a moderate level of leverage, which is manageable but has increased compared to previous years. The return on equity is negative, reflecting ongoing losses. The equity ratio is healthy, showing that a good portion of the company's assets are financed by equity. The balance sheet shows stability but highlights the need for improved profitability.

Cash Flow

Oscar Health's cash flow situation is concerning, with a significant decline in free cash flow growth of -38.78% in the TTM. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is close to 1, suggesting that cash flows are closely aligned with earnings, but the overall cash flow position is weak.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	11.29B	9.18B	5.86B	4.13B	1.92B	589.64M
Gross Profit	11.29B	9.18B	5.86B	4.13B	1.92B	589.64M
EBITDA	-183.34M	89.31M	-212.00M	-572.17M	-551.25M	-390.98M
Net Income	-244.09M	25.43M	-270.73M	-606.27M	-572.61M	-406.82M
Balance Sheet
Total Assets	5.75B	4.84B	3.60B	4.53B	3.32B	2.27B
Cash, Cash Equivalents and Short-Term Investments	3.04B	2.15B	2.56B	2.96B	1.69B	1.19B
Total Debt	686.29M	299.56M	298.78M	298.00M	0.00	142.49M
Total Liabilities	4.72B	3.82B	2.80B	3.63B	1.93B	3.57B
Stockholders Equity	1.02B	1.01B	803.97M	890.38M	1.39B	-1.30B
Cash Flow
Free Cash Flow	735.64M	950.30M	-297.74M	351.34M	-207.63M	208.71M
Operating Cash Flow	769.77M	978.19M	-272.16M	380.35M	-181.75M	222.73M
Investing Cash Flow	-223.80M	-1.39B	577.19M	-226.52M	-774.51M	-344.71M
Financing Cash Flow	394.86M	68.39M	6.45M	301.11M	1.24B	611.71M

Oscar Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 18.16
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSCR, the sentiment is Positive. The current price of 18.16 is above the 20-day moving average (MA) of 15.78, below the 50-day MA of 18.20, and above the 200-day MA of 15.97, indicating a neutral trend. The MACD of -0.71 indicates Negative momentum. The RSI at 57.54 is Neutral, neither overbought nor oversold. The STOCH value of 91.20 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSCR.

Oscar Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HUM	63 Neutral	$28.61B	22.29	7.15%	1.21%	9.87%	-5.58%
MOH	61 Neutral	$7.47B	9.01	19.71%	―	13.71%	-18.02%
ALHC	59 Neutral	$3.83B	―	-15.06%	―	47.39%	85.35%
CNC	58 Neutral	$19.49B	―	-21.93%	―	14.92%	-286.72%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CLOV	50 Neutral	$1.27B	-21.16	-16.90%	―	15.23%	38.79%
OSCR	45 Neutral	$4.81B	-16.15	-22.32%	―	37.38%	-912.18%

Oscar Health Corporate Events

Oscar Health’s Earnings Call: Growth Amid Challenges

Oscar Health’s recent earnings call presented a mixed sentiment, reflecting both optimism and challenges. While the company showcased impressive revenue growth and a substantial increase in membership, it continues to grapple with issues such as a rising medical loss ratio and operational losses. The introduction of innovative products and AI integration suggests promising future potential, yet current financial metrics reveal significant hurdles that need to be addressed.

Oscar Health Reports Q3 2025 Financial Results

Oscar Health, Inc. is a healthcare technology company that offers individual and family health plans, focusing on providing affordable and innovative healthcare solutions through its technology platform. The company is dedicated to enhancing the member experience and expanding its market presence.

Oscar Health Enters $250M Exchange Agreement with Oasis

On November 3, 2025, Oscar Health entered into an exchange agreement with Oasis FD Holdings, LP, allowing the exchange of up to $250 million of its convertible senior notes for shares and cash, with $187.5 million already exchanged by November 5, 2025. This move is part of Oscar’s strategy to manage its capital structure and reduce future interest obligations. Additionally, Oscar reported its third-quarter 2025 financial results, showing increased revenue but also higher losses compared to the previous year, reaffirming its full-year 2025 guidance and highlighting its focus on market expansion and cost management.

The most recent analyst rating on (OSCR) stock is a Hold with a $19.50 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.

Oscar Health Issues $410M Convertible Notes for Growth

On September 18, 2025, Oscar Health, Inc. issued $410 million in Convertible Senior Subordinated Notes due 2030, with net proceeds of approximately $395.8 million. The funds will support strategic initiatives, including AI-driven expansion and enhanced consumer healthcare experiences, while also addressing potential growth opportunities like premium tax credits.

The most recent analyst rating on (OSCR) stock is a Sell with a $11.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.

Oscar Health Announces $355M Convertible Notes Offering

On September 16, 2025, Oscar Health announced the pricing of its upsized $355 million offering of 2.25% convertible senior subordinated notes due 2030, aimed at scaling long-term growth and adoption in the individual market. The proceeds from this offering will support general corporate purposes, including strategic AI initiatives and potential extension of premium tax credits, while also managing share dilution through capped call transactions.

The most recent analyst rating on (OSCR) stock is a Sell with a $11.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.

Oscar Health Amends Investment Agreement for $350M Offering

On September 11, 2025, Oscar Health, Inc. amended its investment agreement to facilitate a private offering of $350 million in convertible senior subordinated notes due 2030. The proceeds from this offering are intended to support Oscar’s long-term growth initiatives, including strategic AI projects and enhancing consumer healthcare experiences, as well as potentially terminating its revolving credit facility.

The most recent analyst rating on (OSCR) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.

Oscar Health to Reaffirm 2025 Guidance at Conference

Oscar Health, Inc. announced its participation in the 2025 Wells Fargo Healthcare Conference on September 3, 2025. During the event, the company plans to reaffirm its updated full-year 2025 guidance, which was initially shared in its preliminary financial results for the second quarter of 2025. This move is likely to impact the company’s operations by reinforcing its financial outlook and could influence stakeholder confidence.

The most recent analyst rating on (OSCR) stock is a Buy with a $19.00 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.